+91-8668442535

Cervical Cancer Treatment Market By Product (Chemotherapy, Targeted Therapy, Surgical Procedure, Radiation Therapy and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2018 to 2026. Cervical cancer occurs in women in an age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer, which is sexually transmitted. Cervical cancer can be avoided by performing an early screening test and immunizing against HPV infection with Gardasil.

It is quite obvious that the generic market has the major economic share in the cervical cancer treatment market; however, the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.

Market Synopsis

Affordable reimbursement scenarios drive the chemotherapy market's growth.

Chemotherapy is currently the dominant product segment in the cervical cancer treatment market. Drugs such as cisplatin, carboplatin, paclitaxel, doxorubicin, and gemcitabine are employed for the treatment of cervical cancer in advanced stages. Radiation therapy, such as external beam therapy and brachytherapy, is given concurrently with chemotherapy in some stages of cervical cancer to give an excellent synergistic effect. The side effects associated with both therapies are severe, thereby leading to the need for targeted drug therapy. Avastin (bevacizumab) and Keytruda (pembrolizumab), etc., are used in cancer immunotherapy, which possess impressive clinical efficacy, dose tolerance, and patient compliance. Targeted drug therapy will be the fastest-growing market during the forecast period owing to the strong drug pipeline in phase III clinical trials, such as nimotuzumab and atezolizumab. Cervical hysterectomy involves the removal of the uterus, cervix, and sometimes the fallopian tubes in women suffering from early-stage cervical cancer.

The increasing number of patients screened for cervical cancer drives market growth in North America.

North America is the clear leader in the geographical segment of the cervical cancer treatment market. As per the latest research findings of the American Cancer Society, in 2019, approximately 13,170 new cases were diagnosed with cervical cancer, and around 4,250 women will die from cervical cancer. The rising prevalence of cervical cancer and increasing public health awareness resulting in early screening and medical intervention drive the market's growth in North America. According to the facts presented by the World Health Organization (WHO), it is estimated that in the European region, 25,000 women will die from cervical cancer. The existence of major players such as Merck & Co., Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., etc., propels the cervical cancer market's growth in the European region. Asia Pacific will register outstanding growth during the forecast period owing to proactive government policies in early screening and medical intervention to curb the mortality related to cervical cancer and the presence of a huge generic market.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by product and geography.

Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F. Hoffmann-La-Roche AG, GlaxoSmithKline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Varian Medical Systems, Inc.

Key questions are answered in this report.

  • What are the latest market trends prevailing in the cervical cancer treatment market?
  • Which biopharmaceutical companies are competing in the cervical cancer treatment market?
  • What are the clinical manifestations occurring in cervical cancer?
  • What are the screening tests performed and the treatment regimen adopted for the treatment of cervical cancer?
  • What led to the rise of targeted therapy, and how will it perform during the forecast period from 2018 to 2026?
  • What are the major attributes responsible for the dominance of North America in the cervical cancer treatment market?

Frequently Asked Questions:

The market for Cervical Cancer Treatment Market is expected to reach XX Mn by 2026.

The Cervical Cancer Treatment Market is expected to see significant CAGR growth over the coming years, at 5.2%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Eli Lilly & Company, F. Hoffmann-La-Roche AG, GlaxoSmithKline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jan 2019
Category:  Pharmaceuticals
Report ID:   59521
Report Format:   PDF
Pages:   120
Rating:    4.4 (56)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support